Skip to main content
RNAZ logo

TransCode Therapeutics, Inc.

RNAZNASDAQHealthcareBiotechnology

$1.70Today:- (-)1Y −88.18%

As of Oct 16, 2026 close

Market cap
$1.72M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.52$15.49
Volume (live)
-
Avg. volume (3M)
46.60K

TransCode Therapeutics (RNAZ) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), TransCode Therapeutics posted a net loss of $34.66M, compared with a net loss of $16.75M a year earlier.

TransCode Therapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
TransCode Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Mar 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.00-0.000.00-0.000.000.00
Cost of Revenue0.000.530.52-0.100.04-0.000.000.00
Gross Profit0.00-0.53-0.52--0.10-0.04-0.000.000.00
Operating Expenses
Research & Development13.429.6212.2612.2610.232.752.750.280.230.08
Selling, General & Administrative5.775.516.647.158.403.353.400.440.230.30
Operating Expenses17.9215.1318.9018.5017.556.116.150.730.460.38
Operating Income-17.92-15.66-19.42-18.50-17.55-6.15-6.15-0.73-0.46-0.38
Other Income/Expense
Interest Income0.080.000.010.010.020.000.000.000.000.07
Interest Expense0.010.030.060.060.030.10-0.100.390.160.00
Other Income/Expense-16.59-1.090.870.871.07-0.69-0.69-1.62-0.15-0.07
Income
Income Before Tax-34.44-16.75-18.55-18.55-17.56-6.84-6.84-2.34-0.61-0.45
Income Tax Expense0.230.000.00-0.000.00-0.000.000.00
Net Income-34.66-16.75-18.55-18.55-17.56-6.84-6.84-2.34-0.61-0.45
Net Income - Continuous Operations-34.66-16.75-18.55-18.55-17.56-6.84-6.84-2.34-0.61-0.45
Net Income - Discontinued Operations----------
EBITDA-34.31-16.19-17.97-17.97-17.43-6.71-6.11-1.95-0.45-0.07
EBIT-34.43-16.73--18.49-17.53--6.15-0.73--
Depreciation & Amortization0.110.530.520.520.100.040.040.000.000.38
Earnings Per Share
Basic EPS-53.00-47.00-3454.00-27314.00-1033233.00-648.00-748.00-294.00-72.00-2359.00
Diluted EPS-53.00-47.00-3454.00-27314.00-1033233.00-648.00-748.00-294.00-72.00-2359.00
Basic Shares Outstanding0.690.360.010.000.000.010.000.010.010.00
Diluted Shares Outstanding0.690.360.010.000.000.010.000.010.010.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TransCode Therapeutics Financial Statements

Is TransCode Therapeutics profitable?

No. TransCode Therapeutics reported a net loss of $34.66M in fiscal 2025. In fiscal 2024 it lost $16.75M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition